Skip to main content
Premium Trial:

Request an Annual Quote

Indianapolis Biomarker Cancer Dx Firm Reels in $6.3M in Series A Funding

NEW YORK (GenomeWeb News) – Indianapolis-based company CS-Keys has gained nearly $6.3 million in Series A financing from previous and new investors, the company said today.
 
The cash infusion will fund the company’s initial product offering, the caPCNA Key Stain, a stain used to help pathologists detect the occurrence and re-occurrence of several types of cancer, including colorectal, breast, prostate, and ovarian cancers.
 
The financing round included investments from Triathlon Medical Ventures, which seeded the company, Clarian Health Ventures, Prolog Ventures, Ceres Venture Fund, and Spring Mill Venture Partners.
 
The company also is developing other biomarker-based diagnostics, including the caPCNA Elisa and caPCNA Cytology products.
 
 

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.